The pharmaceutical company will hold back more funding for existing portfolio companies, and has disclosed the fund's two latest investments.

Denmark-based pharmaceutical firm Novo announced on Monday that its Repair Impact Fund is shifting strategy to support more portfolio companies at a later stage. The corporate launched the fund in early 2018 with $165m and a brief to invest $20m to $40m per year in drug developers looking to target antimicrobial resistance over three to…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.

Robert Lavine

Robert Lavine is special features editor for Global Venturing.